The aberrant expression of microRNAs (miRNAs) has emerged as an important hallmark of cancer. However, the molecular mechanisms underlying the changes in miRNA expression remain unclear. In this study, we discovered a novel epigenetic mechanism of miR-506 regulation and investigated its functional significance in pancreatic cancer. Sequencing analysis revealed that the miR-506 promoter is highly methylated in pancreatic cancer tissues compared with non-cancerous tissues. Reduced miR-506 expression was significantly associated with clinical stage, pathologic tumor status, distant metastasis and decreased survival of pancreatic cancer patients. miR-506 inhibited cell proliferation, induced cell cycle arrest at the G1/S transition and enhanced apoptosis and chemosensitivity of pancreatic cancer cells. Furthermore, we identified sphingosine kinase 1 (SPHK1) as a novel target of miR-506, the expression of which inhibited the SPHK1/Akt/NF-κB signaling pathway, which is activated in pancreatic cancer. High SPHK1 expression was significantly associated with poor survival in a large cohort of pancreatic cancer specimens. Our data suggest that miR-506 acts as a tumor suppressor miRNA and is epigenetically silenced in pancreatic cancer. The newly identified miR-506/SPHK1 axis represents a novel therapeutic strategy for future pancreatic cancer treatment.
INTRODUCTION
Pancreatic cancer remains one of the deadliest cancers, with a 5-year overall survival rate of less than 7%. 1 This poor prognosis is due to its late presentation, early metastasis and unresponsiveness to most treatment options. 2 Surgical resection is the only curative treatment; however, only~15-20% of tumors are resectable at the time of diagnosis. 3 A large proportion of patients are diagnosed with locally advanced or metastatic disease at the time of presentation, 1 and these patients receive chemoradiation therapy. Nevertheless, pancreatic cancer responds poorly to both chemotherapy and radiation. 4 Although gemcitabine-based chemotherapy is standard treatment for advanced pancreatic cancer and has improved patient prognosis, its effect is limited because of high drug resistance. 5 Therefore, the development of new diagnostic and treatment strategies for pancreatic cancer is urgently needed.
MicroRNAs (miRNAs) are a class of small noncoding RNAs (~22 nt) that function in post-transcriptional regulation mainly by binding to the 3′-untranslated region (3′-UTR) of target mRNAs, resulting in mRNA degradation or inhibition of translation. 6 Altered miRNA expression has been reported in almost all types of human cancers. miRNAs can function as oncogenes or tumor suppressor genes, involving multiple pathways and cell functions in cancer development and progression, such as proliferation, apoptosis, invasion and resistance to therapy. 7 To date, a series of miRNAs (including miR-21, miR-34a, miR-30d, miR-155 and miR-203) has been shown to be associated with tumor progression and overall survival in patients with pancreatic cancer. 8, 9 In an integrated data analysis, Frampton et al. 10 identified that miR-21, miR-23a and miR-27a functioned as cooperative repressors of a network of tumor suppressor genes, and high levels of a combination of these miRNAs were correlated with shorter survival times in pancreatic ductal adenocarcinoma (PDAC) patients. Previous studies from our group demonstrated that miR-15a inhibits cell proliferation and the epithelial-tomesenchymal transition in PDAC by downregulating Bmi-1 expression. 11 These studies indicate that several miRNAs are involved in the tumorigenesis of PDAC. Recently, miR-506, a member of an X chromosome-linked miRNA cluster in the primate, 12 was found to have pivotal roles in several cancer types. [13] [14] [15] However, the role of miR-506 is complicated, even contradictory, in the reported cancer types. For instance, miR-506 acts as a tumor suppressor in ovarian 13 and lung 14 cancer, but functions as an oncogene in melanomas, 15 which indicates that miR-506 may function in a tissue type-dependent manner. Nevertheless, whether and how miR-506 is involved in the pathogenesis of pancreatic cancer is yet to be investigated.
In this study, we discovered that miR-506 acts as a novel tumor suppressor in pancreatic cancer. The tumor-suppressive function of miR-506 is mediated in part by the suppression of sphingosine kinase 1 (SPHK1) expression, thereby inhibiting Akt/NF-κB signaling. We found that miR-506 suppressed pancreatic cancer cell growth both in vitro and in vivo. In addition, the ectopic expression of miR-506 caused cell cycle arrest and enhanced pancreatic cancer cell apoptosis and chemosensitivity. We further revealed the clinical relevance of miR-506 in pancreatic cancer, as the expression of miR-506 was significantly reduced in pancreatic cancer due to hypermethylation of its promoter. Reduced miR-506 expression significantly correlated with a poor prognosis of pancreatic cancer patients.
RESULTS miR-506 is aberrantly downregulated in pancreatic cancer tissues and correlates with disease progression To investigate the expression level and significance of miR-506 in pancreatic cancer, we first performed quantitative real-time PCR (qRT-PCR) to evaluate miR-506 expression in 13 matched pairs of pancreatic cancer and adjacent non-cancerous tissues. The results showed that miR-506 expression was significantly downregulated in pancreatic cancer tissues compared with adjacent non-cancerous tissues ( Figure 1a) . Consistently, the expression of miR-506 was clearly reduced in pancreatic cancer tissues compared with normal pancreatic tissues ( Figure 1b ). Clinicopathological analyses of 84 pancreatic cancer patients showed that a decrease in miR-506 expression was significantly correlated with clinical stage, pathologic tumor status and distant metastasis (Supplementary Table 1 ). In addition, Kaplan-Meier survival analysis showed that patients with lower miR-506 expression levels had significantly reduced 5-year overall survival rates ( Figure 1c) . A multivariate Cox regression analysis showed that low miR-506 expression was an independent poor prognostic factor in pancreatic cancer (hazard ratio, 1.880; 95% confidence interval, 1.048-3.026; P = 0.033; Supplementary Table 2) . These results suggest that the downregulation of miR-506 might promote the progression of pancreatic cancer. miR-506 inhibits pancreatic cancer cell proliferation in vitro and in vivo and induces cell cycle arrest To investigate its biological function in pancreatic cancer, miR-506 was ectopically expressed via a lentiviral infection system to establish two stable pancreatic cancer cell lines, AsPC-1 and PANC-1, both of which have low levels of miR-506 (Supplementary Figure 1a) . Cell proliferation assays showed that miR-506 overexpression significantly suppressed pancreatic cancer cell proliferation (Figures 2a and b) . In contrast, the proliferation rate of the pancreatic cancer cell lines PANC-1 and BxPC-3 that were transiently transfected with miR-506 inhibitors was significantly increased compared with negative control cells (Supplementary Figures 1b, 2a and b) . To determine whether miR-506 upregulation inhibits pancreatic cancer cell growth in vivo, AsPC-1 cell lines that were transfected with a control vector or miR-506 were implanted subcutaneously into nude mice. The tumors in the nude mice inoculated with AsPC-1/ miR-506 cells grew more slowly than the tumors in the nude mice inoculated with AsPC-1/vector cells (Supplementary Figure 3) . After 30 days, the weights of the tumors derived from the AsPC-1/miR-506 cells were significantly lower than the weights of those from the control cells (Figure 2c ). Immunohistochemistry analysis revealed lower Ki-67 levels in tumors from the AsPC-1/miR-506 group compared with those from the AsPC-1/vector group (Figure 2d) . Collectively, our results indicate that miR-506 suppresses pancreatic cancer cell growth both in vitro and in vivo. Moreover, the functional impact of miR-506 on the cell cycle was analyzed using flow cytometry. Figures 2c and d) .
miR-506 induces apoptosis and enhances the chemosensitivity of pancreatic cancer cells We next measured the effect of miR-506 on apoptosis and chemosensitivity of pancreatic cancer cells. For the apoptosis assay, pancreatic cancer cells were harvested after 48 h of incubation, stained with 50 μg/ml propidium iodide and Annexin V-fluorescein isothiocyanate and subsequently analyzed via flow cytometry. miR-506-mimic transfection resulted in a significant increase in the percentages of cells undergoing apoptosis (Figures 3a and b; Supplementary Figure 1c) , whereas miR-506 inhibition noticeably prevented apoptosis of PANC-1 and BxPC-3 cells (Supplementary Figures 2e and f) . To study the effects of miR-506 on the chemosensitivity of pancreatic cancer cells, various gemcitabine concentrations were used. AsPC-1 and PANC-1 cells were transfected with miR-506 mimics 24 h before gemcitabine treatment, and the antiproliferative effects of (20 μM) for 48 h using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control. *P o0.05; **P o0.01. gemcitabine were measured 48 h after treatment using the CCK-8 assay. The results revealed that the miR-506 mimics noticeably enhanced the chemosensitivity of the cells to gemcitabine (Figures 3c and d) , whereas miR-506 inhibitors significantly conferred chemoresistance to PANC-1 and BxPC-3 cells (Supplementary Figures 2g and h) . Moreover, the noted effect of miR-506 on apoptosis was confirmed, as increased activating cleavage of PARP and caspase-3 was induced by gemcitabine in the pancreatic tumor cells that overexpressed miR-506 (Figure 3e ). miR-506 targets SPHK1 in pancreatic cancer On the basis of miRNA target analysis algorithms (miRanda and TargetScan), SPHK1 is a potential target mRNA of miR-506 (Figure 4a ). We chose SPHK1 as a validation target, as it has been shown to be involved in various relevant biological processes, such as cell proliferation, apoptosis and chemoresistance. 16 Western blot analysis revealed that miR-506 overexpression significantly reduced the expression of SPHK1 in AsPC-1 and PANC-1 pancreatic cancer cells (Figure 4b ), whereas miR-506 inhibitors noticeably increased the expression of SPHK1 in PANC-1 and BxPC-3 cells (Supplementary Figure 4a) . However, qRT-PCR analysis revealed that the mRNA expression of SPHK1 did not notably change (Supplementary Figure 4b) , suggesting that the suppressive effect of miR-506 on SPHK1 was mainly via translational suppression. Using a dual-luciferase reporter system, we showed that the coexpression of miR-506 significantly inhibited the firefly luciferase reporter activity of the wild-type SPHK1 3′-UTR but not the mutant 3′-UTR (Figure 4c ), indicating that SPHK1 is a direct target of miR-506.
To further confirm that SPHK1 is a direct target of miR-506, we detected the endogenous expression levels of miR-506 and SPHK1 in five pancreatic cancer cell lines and an immortalized human pancreatic ductal epithelial cell line to investigate the relationship between the expression levels of miR-506 and SPHK1. qRT-PCR and western blot analysis showed a significant inverse correlation between the levels of miR-506 and SPHK1 proteins (Figures 4d and e) . We also examined the expression levels of miR-506 and SPHK1 in 13 pairs of matched pancreatic cancer tissues and adjacent non-cancerous tissues. Among the 13 pairs of pancreatic cancer tissues, we observed a significant inverse correlation between the expression of miR-506 and SPHK1 (Figures 4f-h ). Moreover, we subsequently examined SPHK1 expression in subcutaneous xenotransplanted tumors of nude mice via immunohistochemistry. Lower SPHK1 levels were observed in tumors from the AsPC-1/miR-506 cells compared with those from the AsPC-1/vector group ( Supplementary Figures 5a and b) . These results indicate that miR-506 downregulation by promoter methylation may be the primary mechanism of SPHK1 upregulation in pancreatic cancer. Increased SPHK1 expression is associated with a poor prognosis in pancreatic cancer The protein expression status of SPHK1 was further investigated in an additional 388 archival formalin-fixed paraffin-embedded pancreatic cancer tissues and 20 normal pancreatic tissues using immunohistochemistry. SPHK1 was markedly upregulated in pancreatic cancer tissues but was nearly undetectable in normal pancreatic tissues (Figure 5a ). Statistical analyses revealed that SPHK1 expression was significantly associated with the clinical stage, the pathologic tumor status, lymph node status and distant metastasis of patients with pancreatic cancer (Supplementary Table 3 ). A Kaplan-Meier survival analysis revealed that patients with high SPHK1 expression had significantly lower 5-year overall survival rates (P o 0.001; Figure 5b) . Notably, SPHK1 expression also significantly correlated with overall survival in both the early clinical subgroups (stages I and II) and the advanced-disease group (stages III and IV; Figures 5c and d), indicating that SPHK1 could be a valuable prognostic marker for pancreatic cancer patients at all disease stages. In addition, a multivariate Cox regression analysis showed that high expression of SPHK1 was an independent poor prognostic factor in pancreatic cancer (hazard ratio, 1.395; 95% confidence interval, 1.107-1.758; P = 0.005; Supplementary Table 4) . SPHK1 silencing recapitulates the effects of miR-506 in pancreatic cancer cells To determine the functional impacts of SPHK1 on pancreatic cancer cells, two specific small interfering RNAs against SPHK1 mRNA, si-SPHK1-1 and si-SPHK1-2, significantly reduced the expression of SPHK1 protein (Supplementary Figure 6a) and clearly inhibited the proliferation of both AsPC-1 and PANC-1 cells (Figures 6a and b) . Moreover, we conducted a knockdown approach using a lentiviral infection system to establish AsPC-1 and PANC-1 transfectants that stably express SPHK1 short hairpin RNA (Supplementary Figure 6b) . Compared with control cells, SPHK1-RNAi inhibited pancreatic cancer cell proliferation both in vitro (Supplementary Figure 6c) and in vivo ( Supplementary  Figures 6d and e) . Both si-SPHK1-1 and si-SPHK1-2 induced G1 − S arrest (Figures 6c and d) and apoptosis (Figures 6e and f) of AsPC-1 and PANC-1 cells. In addition, the chemosensitivity of AsPC-1 and PANC-1 cells to gemcitabine was significantly increased because of si-SPHK1 treatment (Figures 6g and h) . These results suggest that SPHK1 is one of the key functional mediators for miR-506 in pancreatic cancer cells. The suppression of proliferation, the blockade of cell cycle progression, the enhancement of apoptosis and the chemosensitivity observed due to the silencing of SPHK1 were similar to the phenotype induced by the restored expression of miR-506 in pancreatic cancer cells. These results suggest that miR-506-mediated downregulation of SPHK1 is one of the major mechanisms that inhibit pancreatic cancer growth and progression.
Re-introduction of SPHK1 abrogates the miR-506-induced effects on cell proliferation and apoptosis To further confirm that the functional impact of miR-506 in pancreatic cancer is mediated by the suppression of SPHK1, we re-introduced SPHK1 expression in miR-506-expressing cells to observe the direct antagonizing effect of miR-506. We constructed a lentiviral expression vector of SPHK1 without the 3′-UTR and infected miR-506-expressing cells. As shown in Figure 7a , SPHK1 expression was restored after SPHK1 lentiviral infection. Functional studies showed that the re-introduction of SPHK1 enhanced the proliferation of miR-506-expressing cells (Figure 7b ). In addition, the inhibitory effect of miR-506 on the G1/S phase transition of the cell cycle was also rescued by enforced SPHK1 expression miR-506 induces pancreatic cancer cell growth suppression and apoptosis via the SPHK1/Akt/NF-κB signaling pathway SPHK1 is associated with the promotion of Akt/NF-κB-dependent cell proliferation and apoptosis. 17 Therefore, we next examined whether the Akt/NF-κB pathway is involved in miR-506-SPHK1-mediated cell growth and apoptosis in pancreatic cancer. Interestingly, western blot analysis showed that miR-506 overexpression decreased Akt/NF-κB signaling, whereas the ectopic expression of SPHK1 blocked the miR-506-mediated inactivation of the Akt/NF-κB pathway (Figure 7a) . Moreover, an NF-κB reporter assay showed that SPHK1 upregulation could abrogate miR-506-induced suppression of NF-κB transcriptional transactivating activity in both AsPC-1 and PANC-1 cells (Figure 7d) .
To further determine whether the Akt/NF-κB pathway has a role in miR-506-SPHK1-mediated tumor progression, we performed immunohistochemistry in human pancreatic cancer tissues for SPHK1, Akt, NF-κB(p65), Bcl-2, caspase-3 and Ki-67 and analyzed their correlation with miR-506 expression (determined via qRT − PCR). As shown in Figure 8 , miR-506 expression inversely correlated with SPHK1, Akt, NF-κB(p65) and Bcl-2 protein expression in the 84 cases of pancreatic cancer (P o 0.05 for all), which was consistent with the in vitro results. Moreover, high miR-506 expression was significantly associated with low Ki-67 and high caspase-3 expression (P o 0.05). Altogether, our results from the in vitro and human tumor samples showed that miR-506 suppressed the SPHK1/Akt/NF-κB signaling pathway and consequently reduced cell proliferation and promoted apoptosis in pancreatic cancer. Microarray analysis identified additional potential target genes and pathways of miR-506, further elucidating the mechanism behind its tumor-suppressive effect It should be noted that any given miRNA has the capacity to exert its function on dozens, if not hundreds, of target genes, 18 and we cannot exclude the possibility that other target genes are involved in the tumor-suppressive role of miR-506. To identify additional miR-506 target genes and the mechanisms behind its tumorsuppressive effect, we performed global microarray analysis of mRNA expression in the miR-506-overexpressing AsPC-1 pancreatic cancer cell line and a negative control. The array results are listed on the website http://www.ncbi.nlm.nih.gov/geo/query/ acc.cgi?acc = GSE76280, and the gene expression omnibus accession number is GSE76280. We identified that miR-506 could potentially enhance the expression of 144 genes and downregulate the expression of 78 genes, respectively (Supplementary Figure 7a) . Collectively, miR-506 could potentially target~10 pathways including the tumor-related PI3K-Akt pathway that was intensively investigated in this study (Supplementary Figure 7b) . In addition, a Venn diagram demonstrated the overlap between the genes downregulated by the miR-506 and the common miR-506 target genes in three Databases (miRanda, miRDB and Targetscan; Supplementary Figure 7c ). The use of three different bioinformatics predicted that target algorithm will increase the probability of true miR-506-mediated targets. These results provide a better understanding of the global impact of miR-506-mediated targets and pathways in pancreatic cancer, in addition to the key target SPHK1 and the major PI3K-Akt pathway. Hypermethylation mediates miR-506 silencing in pancreatic cancer Because miR-506 has a key role in pancreatic cancer progression and chemoresistance, we further investigated the mechanism responsible for its downregulation in cancer tissues. We identified five CpG sites in the promoter region of the miR-506 gene in pancreatic cancer tissues (Supplementary Figure 8a) . Sequencing analysis revealed that, among the five methylation sites of the miR-506 promoter, the fifth site displayed hypermethylation in pancreatic cancer tissues compared with adjacent non-cancerous tissues (Figure 9a) , whereas there were no differences in methylation of the other four sites between cancer tissues and adjacent non-cancerous tissues (Supplementary Figures 8b − e) . The hypermethylation of the miR-506 promoter in pancreatic cancer tissues was confirmed using an additional 45 cancer tissues and 10 normal pancreatic tissues (Figure 9b ). The impact of hypermethylation of the miR-506 promoter on miR-506 expression was quantified via qRT − PCR using total RNA isolated from paired normal and pancreatic cancer tissues. A high level of promoter methylation in cancer tissues was significantly associated with reduced miR-506 expression compared with adjacent noncancerous tissues (Figure 1a) . Furthermore, a significant inverse correlation between miR-506 promoter methylation and miR-506 expression was observed (Figures 9c and d) . In addition, 5-aza-2'-deoxycitidine (5-aza-CdR), a demethylating agent, markedly increased miRNA-506 expression, indicating that DNA methylation was responsible for miR-506 gene silencing (Figure 9e ). We also evaluated the association between DNA methylation and patient survival time in 45 pancreatic cancer patients. We found that miR-506 hypermethylation was associated with a shorter survival time (Figure 9f ). Taken together, our results suggest that hypermethylation at least partially mediates miR-506 silencing in pancreatic cancer.
DISCUSSION
Dysregulation of miRNAs, which can result from aberrant DNA methylation, has been demonstrated to contribute to pancreatic cancer tumorigenesis. 19, 20 In this study, we found that miR-506 expression was reduced in pancreatic cancer, mediated by hypermethylation of the promoter region of the miR-506 gene and significantly associated with poor prognosis. miR-506 Figure 9 . Hypermethylation mediates miR-506 silencing in pancreatic cancer. (a) The DNA methylation levels of site five were detected in 13 paired pancreatic cancer tissues and adjacent non-cancer tissues by pyrosequencing. The differences in DNA methylation levels between cancer tissues and adjacent non-cancer tissues were calculated using Student's t-test. Aj: adjacent non-cancerous tissue; T: pancreatic cancer. The P-values were determined using a log-rank test.
inhibited pancreatic cancer cell growth in vitro and in vivo and enhanced apoptosis and chemosensitivity through downregulating SPHK1. Silencing of SPHK1 recapitulated the effects of miR-506 overexpression, whereas enforced expression of SPHK1 reversed the suppressive effects of miR-506. This functional impact of miR-506 was mediated directly through SPHK1 to inhibit Akt/NF-κB signaling. These findings support the important roles of miR-506 in suppressing the tumorigenesis of pancreatic cancer.
Altered expression of miRNA is strongly implicated in cancer, and recent studies have shown that certain miRNA genes may be silenced in human tumors by aberrant CpG island hypermethylation. 21, 22 Aberrant hypermethylation has also been reported to regulate the expression of specific miRNAs in pancreatic cancer, including miR-124, miR-132 and miR-615-5p. 19, 20, 23 Moreover, in a recent report, Yang et al. demonstrated that promoter DNA methylation attenuated miR-506 expression in human ovarian cancer. However, the methylation status of miR-506 in pancreatic cancer has remained unclear. In this study, we first performed pyrosequencing to evaluate the detailed methylation patterns of five CpG islands in the promoter region of miR-506 and found that the miR-506 promoter was more highly methylated in pancreatic cancer tissues compared with adjacent non-cancerous tissues and normal controls. In addition, we showed that promoter hypermethylation resulted in miR-506 silencing in pancreatic cancer and that miR-506 hypermethylation was associated with reduced survival time. Our study suggests that miR-506 may be involved in pancreatic cancer pathogenesis and progression; furthermore, it may serve as a prognostic biomarker of pancreatic cancer.
The reported expression patterns and roles of miR-506 markedly differ among various malignancies. In ovarian cancer, miR-506 was identified as a key epithelial-to-mesenchymal transition inhibitor that inhibited cell migration and invasion; thus, the clinically downregulated miR-506 expression in tumor tissues was significantly correlated with poor prognosis. 13 Similar results have been demonstrated in cervical cancer, 24 breast cancer 25 and gastric cancer, 26 indicating that miR-506 also acts as a tumor suppressor in these cancer types. However, miR-506 is upregulated and functions as an oncogene to promote proliferation in melanomas 15 and confers chemoresistance in colon cancer. 27 Moreover, miR-506 has been shown to be associated with diverse biological behaviors via the regulation of different target genes. Recent studies have shown that miR-506 prevents TGFβ-induced epithelial-to-mesenchymal transition by targeting SNAI2 13 and can also suppress the expression of vimentin and N-cadherin in ovarian cancer. 28 In addition, miR-506 has been involved in antiproliferative functions through the regulation of its target genes, CDK6 29 and Gli3. 24 These various observations for the roles of miR-506 may not be surprising because the function of certain miRNAs and their target preference may be highly dependent on the cellular and disease context. Although these mechanisms mediated by miR-506 may also be involved in pancreatic cancer, we provide strong evidence that a novel miR-506 epigenetic silencing alteration and targeting SPHK1 promote pancreatic cancer cell proliferation in vitro and in vivo. The restoration of miR-506 induces cell cycle arrest at the G1/S transition and enhances apoptosis and the chemosensitivity of pancreatic cancer cells. Therefore, reduced miR-506 expression promotes the tumorigenesis of pancreatic cancer. SPHK1, the rate-limiting enzyme of sphingosine 1 phosphate synthesis, has been demonstrated to have a crucial role in oncogenesis. 30 Accumulating evidence suggests that SPHK1 expression correlates with various cellular functions in tumors, such as proliferation, apoptosis, chemoresistance and angiogenesis. [31] [32] [33] In addition, SPHK1 activation correlates with the progression of several types of cancer. 17, 34, 35 Moreover, SPHK1 downregulation enhances chemosensitivity to gemcitabine via the targeting of sphingolipid metabolism. 36 We reveal for the first time the key roles of SPHK1 in pancreatic cancer. In this study, we demonstrated that SPHK1 was overexpressed and correlated with poor prognosis in a large cohort of pancreatic cancer specimens. In addition, we revealed that miR-506 bound to the 3′-UTR of SPHK1, resulting in a dramatic reduction in SPHK1 protein levels. On the basis of the observations that SPHK1 silencing recapitulated the effects of miR-506 overexpression, and enforced expression of SPHK1 reversed the suppressive effects of miR-506, our results indicate that the functional roles of miR-506 are mediated by its direct targeting of SPHK1 in pancreatic cancer. It has been reported that SPHK1 is associated with Akt/NF-κB-dependent cell proliferation and apoptosis. 17 Consistent with this observation, we found that miR-506 upregulation significantly inhibited levels of the activated forms of Akt and IKBα. Moreover, we performed immunohistochemistry on serial sections of human pancreatic cancer tissues with antibodies specific for SPHK1, p-Akt, NF-κB and Bcl-2 and showed that the expression of these proteins inversely correlated with miR-506 expression. Thus, our current study suggests that activation of the Akt/NF-κB signaling pathway by SPHK1 may have a pivotal role in miR-506-mediated tumor suppression and enhanced chemosensitivity in pancreatic cancer.
It has been recently demonstrated that both miRNA mimics and anti-miRs are potential novel anticancer therapeutics. Modified anti-miRs, such as peptide nucleic acids, cholesterolconjugated 'antagomirs' and anti-miRNA oligonucleotides, have shown effectiveness in vivo. [37] [38] [39] Notably, MRX34 is entering a Phase 1 trial as the first miRNA mimic for cancer therapy. 40 In this study, our primary data demonstrated that the miR-506 mimics effectively suppress pancreatic cancer cell growth in vitro, revealing its potential therapeutic significance in pancreatic cancer based on an miRNA 'replacement' strategy. Moreover, miRNAs may be promising candidates as biomarkers for early cancer diagnosis and prognosis and for the modification of responses to anticancer treatment. [41] [42] [43] [44] Because the hypermethylation and downregulation of miR-506 were associated with poor prognoses, miR-506 has a strong potential for use as a biomarker for improved management of pancreatic cancer.
In conclusion, we demonstrated that promoter hypermethylation mediated the silencing of miR-506 in pancreatic cancer. Transcriptional repression of miR-506 results in the upregulation of the key target SPHK1, which has an important role in the progression of pancreatic cancer by regulating SPHK1/ Akt/NF-κB signaling. The newly identified miR-506/SPHK1 axis provides crucial mechanistic insights and provides a foundation for miR-506-based therapeutics and biomarkers in pancreatic cancer.
MATERIALS AND METHODS

Cell culture
The human pancreatic cancer cell lines AsPC-1, PANC-1, BxPC-3, Hs766t and CFPAC-1 (ATCC, Manassas, VA, USA) and an immortalized human pancreatic ductal epithelial cell line (HPC-Y5, Chinese Academy of Sciences) were cultured in complete growth medium, as recommended by the manufacturer. Cultured cells were maintained in a humidified 5% CO 2 atmosphere at 37°C.
Tissue samples
Eighty-four fresh-frozen pancreatic cancer samples ( DNA isolation, sodium bisulfite conversion and pyrosequencing analysis Genomic DNA was isolated using the TIANamp Genomic DNA Kit (TIANGEN Biotech, Beijing, China). Sodium bisulfite modification of the DNA was performed using an EZ DNA Methylation-Gold Kit (ZYMO, Beijing, China) according to the manufacturer's protocol. The five CpG sites of the miR-506 promoter region were amplified via PCR using the bisulfite-modified DNA template, forward primers and biotinylated reverse primers according to the established procedures. 13 The primer sequences are listed in Supplementary Table 5. The PCR products were then analyzed via pyrosequencing technology using a PyroMark Gold Q96 Reagent and a PyroMark ID system (Qiagen, Hilton, Germany). Pyro Q-CpG software v. 1.0.9 was used to determine the optimal order of nucleotide addition when designing the assays. The pyrosequencing analysis was performed at Sangon Biotech Co., Ltd. (Shanghai, China).
Quantitative real-time PCR
Total RNA from the tumor cells or tissues was extracted using RNAiso (TaKaRa, Dalian, China). For miR-506 detection, complementary DNA synthesis was performed using a PrimeScript RT reagent kit (TaKaRa), and qRT-PCR was performed with SYBR Premix Ex Taq II (TaKaRa) using a Stratagene Mx3000P real-time PCR system (Agilent Technologies, Santa Clara, CA, USA). The expression levels were normalized to the endogenous small nuclear RNA U6 control. For the mRNA analyses, PrimeScript RT Master Mix (TaKaRa) and SYBR Premix Ex Taq II (TaKaRa) were used. β-actin was used as an endogenous control. The 2 − ΔΔCt method was used to calculate expression relative to the endogenous control. The primer sequences are listed in Supplementary Table 5. Western blotting Protein extracts were separated by electrophoresis in a sodium dodecyl sulfate-polyacrylamide gel (Invitrogen, Camarillo, CA, USA) and transferred onto polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA) for immunoblotting. The membranes were hybridized with a primary antibody at 4°C overnight followed by incubation with a secondary antibody for 1 h at room temperature. Glyceraldehyde-3-phosphate dehydrogenase was used as the loading control. Signals were visualized using a chemiluminescent detection system (Thermo Scientific, Rockford, IL, USA) and exposure to the film. The antibodies used for western blotting are described in Supplementary Table 6 .
Immunohistochemistry
Immunohistochemistry was performed as previously described. 45 Briefly, after blocking, the sections were incubated with primary antibodies overnight, followed by incubation with secondary antibodies and further incubation with the streptavidin-biotin complex (Maixin, Fuzhou, China). The antibodies used for immunohistochemistry are described in Supplementary Table 6 . Ki-67-positive cells were defined as those with brown staining in the nucleus, and the expression was evaluated based on the percentage of positive tumor cells out of 1000 tumor cells. SPHK1-, Akt-, NF-κB(p65)-, BCL-2-and caspase-3-positive cells were defined as those with immunoreactivity in both the cytoplasm and the nucleus, and were quantified using a composite score obtained by multiplying the values of staining intensities (0, no staining; 1, weak staining; 2, moderate staining; 3, strong staining) and the percentage of positive cells (0, 0%; 1, o 10%; 2, 10-50%; 3, 450%). For statistical analyses, the tumor sample cohort was grouped into those with low expression (⩽4) and high expression (⩾6).
Transfection and vector construction miRNA mimics and inhibitors (Qiagen) and small interfering RNAs (sequences listed in Supplementary Table 5) were transiently transfected using Lipofectamine 2000 (Invitrogen) at a final concentration of 100 nM, according to the manufacturer's instructions. Lentiviral miR-506 expression constructs and the negative control lentiviruses were purchased from GeneChem (Shanghai, China). The SPHK1 expression lentivirus was constructed by inserting the SPHK1 open reading frame into the pLenti6.3 vector (Invitrogen). For SPHK1 depletion, human SPHK1-targeting small interfering RNA sequences (GGCTGAAATCTCCTTCACG) were cloned into pENTR vectors to generate pENTR-SPHK1-RNAi lentiviruses (Invitrogen). Lentiviral infection was performed as previously described. 46 Luciferase reporter assay
The wild-type or mutant 3′-UTR sequences of SPHK1 were ligated into the XbaI and FseI sites of the pGL3 vector (GeneChem). HEK293T cells infected with the miR-506 lentivirus or the negative control lentivirus were seeded into 96-well plates. The cells were co-transfected with 50 ng of the pGL3 vector and 10 ng of the pRL-TK vector using Lipofectamine LTX (Invitrogen). Twenty-four hours after transfection, the cells were harvested according to the manufacturer's protocol (Promega, Madison, WI, USA), and firefly and Renilla luciferase activities were measured using a Dual Luciferase Reporter System (Promega) with a Victor X machine (Perkin-Elmer, Boston, MA, USA). For the NF-κB transcriptional activity assay, the pGL4.32[luc2P/NF-κB-RE/ Hygro] plasmid or control luciferase plasmid pGL4.74[hRluc/TK] (Promega) was transfected using the Lipofectamine 2000 reagent (Invitrogen), and luciferase and Renilla signals were measured using a Dual Luciferase Reporter Assay kit (Promega) according to the manufacturer's protocol.
Cell proliferation and chemosensitivity assays
Cell proliferation was measured via WST-8 staining using a Cell Counting Kit-8 (Dojinodo, Shanghai, China) according to the manufacturer's instructions. For the chemosensitivity assays, the cells were treated for 48 h with gemcitabine (Gemzar, Lilly, France), and cell viability was measured using a Cell Counting Kit-8.
Cell cycle and apoptosis assays
For the cell cycle analysis, the transfected cells were collected and fixed in 70% ethanol overnight at − 20°C and stained with propidium iodide (Kaiji, Nanjing, China) in a phosphate-buffered saline solution containing RNase. For the apoptosis assay, the cells were stained with 50 μg/ml propidium iodide and Annexin V-fluorescein isothiocyanate (Kaiji) following the manufacturer's instructions. The data were analyzed using the ModFit 3.3 software (BD Bioscience, Sparks, MD, USA).
Animal experiments
Five-week-old female BALB/c-nu mice were purchased from the Peking University Animal Center (Beijing, China). After 5 days of acclimatization, a total of 2 × 10 6 AsPC-1 cells stably transfected with either miR-506(SPHK1-RNAi) or negative control were injected subcutaneously into the right oxter of each mouse. Tumor volume was calculated using the equation (L × W 2 )/2, and the tumor weights were measured and recorded in grams. The mice were killed on the 30th day after injection. All animal studies were approved by the Institutional Animal Care and Use Committee of the Third Military Medical University.
Complementary DNA microarray analysis Total RNA was isolated from three independent cultures of AsPC-1/ miR-506 cells or AsPC-1/vector cells. RNA quantity and purity were determined using the Nanodrop ND-1000 (NanoDrop Technologies, Wilmington, DE, USA) and denaturing gel electrophoresis. Microarray analysis of mRNA profiles using Agilent Array platforms and the identification of differentially expressed genes were performed by KangChen Bio-tech (Shanghai, China) as previously described. 47 Downregulated miR-506 expression promotes PDAC
